Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
3,124,915
-
Shares change
-
+47,035
-
Total reported value, excl. options
-
$22,028,000
-
Value change
-
+$338,627
-
Number of buys
-
8
-
Number of sells
-
-4
-
Price
-
$7.05
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2016
26 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q4 2016.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,124,915 shares
of 28,495,649 outstanding shares and own 10.97% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (2,631,680 shares), BRIDGEWAY CAPITAL MANAGEMENT INC (100,000 shares), VANGUARD GROUP INC (96,878 shares), Manatuck Hill Partners, LLC (83,958 shares), BlackRock Institutional Trust Company, N.A. (69,217 shares), Artal Group S.A. (64,102 shares), Destination Wealth Management (29,656 shares), GEODE CAPITAL MANAGEMENT, LLC (14,961 shares), Family Management Corp (11,950 shares), and BlackRock Fund Advisors (11,097 shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.